The shares of the pharmaceutical company gained up to 3.06 percent after the company incorporated Auro Trading Private Ltd as a wholly-owned subsidiary of the Company.
With a market capitalization of Rs 61,980.59 crores, Aurobindo Pharma Ltd, On Wednesday, the company shares were trading at Rs 1,057.85, an increase of 3.03 percent from the previous close price.
According to the company filing, Aurobindo Pharma Ltd incorporated Auro Trading Private Ltd as a wholly-owned subsidiary of the Company through 1,00,000 equity shares at a face value of Rs 10 each. The purpose of this incorporation is to carry on trading in generic formulations of business.
In addition to the above paragraph, Evive Biotech a subsidiary of Yifan Pharmaceutical Co. Ltd, and Acrotech Biopharma a subsidiary of Aurobindo Pharma Announce FDA Approval of Ryzneuta™ (Efbemalenograstim alfa Injection) for ChemotherapyInduced Neutropenia.
Examining the business’s financials, the company’s revenue increased 24 percent from Rs. 5,739 crores in FY 2021-22 to Rs 7,219 crores in FY 2022-23. During the same period, Net Profit increased by 83 percent from Rs 410 crores to Rs 752 crores.
The company reported return ratios in the recent financial year with a return on equity (ROE) of 7.5 percent and a return on capital employed (ROCE) of 9.39 percent.
Aurobindo Pharma Ltd’s recent shareholder pattern, The Promoters of the company own 51.83 percent while Retail shareholders own a 7.42 percent stake in the company and Foreign Institutional Investors own a 22.45 percent stake.
The primary business activities of Aurobindo Pharma include the production and distribution of generic medications, active pharmaceutical ingredients, and associated services.
Written by:- Abhishek Singh
